Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-HER2-IV: Trastuzumab-deruxtecan vs SoC in HER2+ Early Breast Cancer
NCT05704829Phase 2Recruiting
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Feb 2024
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Westdeutsche Studiengruppe. Started Feb 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05704829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704829.